Johnson & Johnson (JNJ) Earning Somewhat Favorable Press Coverage, Study Shows

Media headlines about Johnson & Johnson (NYSE:JNJ) have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Johnson & Johnson earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.4328312687455 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

JNJ has been the topic of a number of recent research reports. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. BMO Capital Markets raised their price objective on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective on the stock in a research report on Wednesday, December 20th. JPMorgan Chase downgraded Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Five analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and an average price target of $144.58.

NYSE JNJ traded up $1.38 during trading on Monday, hitting $129.48. The company’s stock had a trading volume of 6,394,948 shares, compared to its average volume of 8,103,099. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. The company has a market cap of $343,679.78, a PE ratio of 17.74, a P/E/G ratio of 2.04 and a beta of 0.74. Johnson & Johnson has a fifty-two week low of $120.95 and a fifty-two week high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The firm had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. During the same period last year, the business posted $1.58 earnings per share. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. sell-side analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.22% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Earning Somewhat Favorable Press Coverage, Study Shows” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/09/johnson-johnson-jnj-earning-somewhat-favorable-press-coverage-study-shows.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Insider Buying and Selling by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply